IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, the rHDL-(1:0), rHDL-(1:0.1), and rHDL-(1:0.5) groups exhibited a dose-dependent reduction in the IL-6-stained area, evident by 6.9%, 4.7%, and 3.4% stained area, respectively, i.e., 2.0-, 2.9-, and 4.1-fold lower, than the IL-6-stained area appeared in the CML + PBS group.